| Bioactivity | SJM-3 is a positive allosteric modulator of different isoforms of the GABAA receptor. SJM-3 binds at the high-affinity benzodiazepine binding site at the α+/γ- subunit interface[1]. |
| Target | GABAA receptor |
| Invitro | SJM-3 binds at the high-affinity benzodiazepine binding site at theα+/γ- subunit interface but effects its action through another site presumably located within the transmembrane domain. The binding affinity of SJM-3 at wild type receptors is determined by displacement of [3H]-Flunitrazepam and [3H]-Ro15-1788 and indicates a Ki of SJM-3 amounting to 218±70 nM and 242±38 nM, respectively[1]. |
| Name | SJM-3 |
| CAS | 1234977-97-9 |
| Formula | C18H15FN4OS |
| Molar Mass | 354.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Simon J Middendorp, et al. Positive modulation of synaptic and extrasynaptic GABAA receptors by an antagonist of the high affinity benzodiazepine binding site. Neuropharmacology. 2015 Aug;95:459-67. |